an innovator, some people argue that this reputation is misplaced. Contrary to earlier expectations, the USA rather than Japan emerged as the leader in the biotech industries in the 1990s, and also many small firms in Japan supply only a few – or just one – other company, thereby limiting their view of the marketplace and the commercial opportunities within it. Despite the increase of international patents, international scientific citations and a positive technology trade balance, the Japanese innovation system is weak in giving birth to radical innovations. The book explores fully these issues, making comparisons with other countries where appropriate. It concludes that the Japanese innovation system has both advantages and disadvantages and contributes to a better understanding of how policy changes take place.

Hide more